Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Onconova Therapeutics
- 07 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015, as per ClinicalTrials.gov record.
- 08 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.